Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Northwestern University
With
Neuronetics
Age
22–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1\. Adults aged 22-80; 2. Have a previous diagnosis of cancer (any type or stage) as confirmed by official medical records; 3. Have a Diagnostic and Statistical Manual (DSM-IV) diagnosis of Major Depressive Disorder; 4. Have a Hamilton Depression Rating (HAM-D) 24-item score of more than 20; 5. Failed to receive satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current depressive episode; 6. All participants must have given signed, informed consent prior to registration in study.
You may not be if
1\. Participant with any type of brain tumor; 2. Participant with cancer with brain metastases; 3. Evidence of the disease at the time of entry into the trial; 4. Presence or recent history of other concurrent cancers, with the following exceptions: a. Participants with completely treated basal or squamous skin cancers could be included in the study if their physicians deem that they are medically stable, b. Participants with completely treated in situ carcinoma of the breast or cervix could be included in the study if they have not had chemotherapy within the past month and their physicians deem that they are medically stable, c. Participants with pre-cancerous lesions in the colon could be included in the study if they have not had chemotherapy within the past month and their physicians deem that they are medically stable; 5. Participant had recent surgery within two weeks of screening; 6. Participants undergoing chemotherapy; 7. Participant pregnant or nursing; 8. Participant with any metallic object in or around their head; 9. Participant with a pacemaker; 10. Participants with unstable suicidal ideation as determined by the patient's treating psychiatrist; 11. Participants with a substance use disorder within the prior six months; 12. Significant history of head injury/trauma as defined by loss of consciousness for more than one hour; 13. Recurring seizures resulting from the head injury; 14. Clear cognitive sequelae from the head injury and cognitive rehabilitation following the injury; 15. Any disorder that would predispose the participant to seizures; 16. Use of concomitant medications that substantially increase seizure risk.; Such drugs could include neuroleptics (ex. haloperidol, droperidol), clozapine, tricyclic antidepressants (ex. amoxapine, clomipramine), bupropion (particularly the immediate release (IR) formulation), donepezil, psychostimulants (ex. methylphenidate), theophylline and/or other drugs that reduce the seizure threshold. For individuals on any of these medicines, a study clinician evaluated the drugs and doses to determine the risks and benefits. These were then discussed with the individual's Primary Care Physician to determine if the individual could be included in the study.
Clareo Health | Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Depression and Anxiety
